Codexis Inc., a leader in enzymatic solutions for therapeutics manufacturing, has entered into an evaluation agreement with Nitto Denko Avecia, a leading contract development and manufacturing organization specializing in oligonucleotide therapeutics. Under the agreement, Nitto Denko Avecia will assess Codexis' ECO Synthesis® Manufacturing Platform, an enzyme-catalyzed technology designed to replace traditional solid-phase oligonucleotide synthesis. The collaboration aims to pave the way for future licensing discussions and broader adoption of the ECO Synthesis platform, advancing scalable and sustainable manufacturing of therapeutic siRNA.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Codexis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN10188) on October 29, 2025, and is solely responsible for the information contained therein.